Cargando…

Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits

PURPOSE: To determine secondary effects of the mandated COVID-19 pandemic closure period for elective treatment on non-elective, injection-based retina care and outcomes. PATIENTS AND METHODS: In this cross-sectional, retrospective analysis of a single-provider outpatient clinic across multiple sate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashkenazy, Noy, Goduni, Lediana, Smiddy, William E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868644/
https://www.ncbi.nlm.nih.gov/pubmed/33568895
http://dx.doi.org/10.2147/OPTH.S296345
_version_ 1783648492648923136
author Ashkenazy, Noy
Goduni, Lediana
Smiddy, William E
author_facet Ashkenazy, Noy
Goduni, Lediana
Smiddy, William E
author_sort Ashkenazy, Noy
collection PubMed
description PURPOSE: To determine secondary effects of the mandated COVID-19 pandemic closure period for elective treatment on non-elective, injection-based retina care and outcomes. PATIENTS AND METHODS: In this cross-sectional, retrospective analysis of a single-provider outpatient clinic across multiple satellites, consecutive patients returning for intravitreal injections (IVIs) of anti-vascular endothelial growth factor or corticosteroids were identified as “delayed” or “undelayed” during a six-week study interval during the COVID-19 pandemic that closely following a mandated period of prohibited elective encounters. A “delayed” encounter was defined as having a follow-up interval exceeding 33% of the recommended cycle. Patients seen for IVIs during the corresponding six-week interval a year previously were identified for study as pre-COVID-19 controls. Main outcome measures included best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) assessment based on findings of intraretinal or subretinal fluid consistent with new or recurrent neovascular events. RESULTS: The study included 183 eyes of 144 patients who underwent IVI-based care from June 18, 2020, through August 7, 2020, compared to 193 eyes of 154 patients injected during the corresponding interval 1 year before. There were 62 eyes of 46 patients seen in the study period later than scheduled (among 144 patients of 183 eyes in total), which represented a larger proportion of delayed patients compared to the previous year (31.9% vs. 14.9%, p<0.0005). Considering the patterns from the control group, the attributed delay due to COVID-19 was 15.0% of patients. The delayed return eyes had a greater decline in BCVA (3 letters), higher rates of worsened OCT results (48%), and prompted reduction in previously prescribed injection intervals (p<0.02). CONCLUSION: The unintended consequence of delayed care of patients on established care regimens should be anticipated, and mitigate strategies considered if similar restrictions are mandated in the future.
format Online
Article
Text
id pubmed-7868644
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78686442021-02-09 Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits Ashkenazy, Noy Goduni, Lediana Smiddy, William E Clin Ophthalmol Original Research PURPOSE: To determine secondary effects of the mandated COVID-19 pandemic closure period for elective treatment on non-elective, injection-based retina care and outcomes. PATIENTS AND METHODS: In this cross-sectional, retrospective analysis of a single-provider outpatient clinic across multiple satellites, consecutive patients returning for intravitreal injections (IVIs) of anti-vascular endothelial growth factor or corticosteroids were identified as “delayed” or “undelayed” during a six-week study interval during the COVID-19 pandemic that closely following a mandated period of prohibited elective encounters. A “delayed” encounter was defined as having a follow-up interval exceeding 33% of the recommended cycle. Patients seen for IVIs during the corresponding six-week interval a year previously were identified for study as pre-COVID-19 controls. Main outcome measures included best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) assessment based on findings of intraretinal or subretinal fluid consistent with new or recurrent neovascular events. RESULTS: The study included 183 eyes of 144 patients who underwent IVI-based care from June 18, 2020, through August 7, 2020, compared to 193 eyes of 154 patients injected during the corresponding interval 1 year before. There were 62 eyes of 46 patients seen in the study period later than scheduled (among 144 patients of 183 eyes in total), which represented a larger proportion of delayed patients compared to the previous year (31.9% vs. 14.9%, p<0.0005). Considering the patterns from the control group, the attributed delay due to COVID-19 was 15.0% of patients. The delayed return eyes had a greater decline in BCVA (3 letters), higher rates of worsened OCT results (48%), and prompted reduction in previously prescribed injection intervals (p<0.02). CONCLUSION: The unintended consequence of delayed care of patients on established care regimens should be anticipated, and mitigate strategies considered if similar restrictions are mandated in the future. Dove 2021-02-03 /pmc/articles/PMC7868644/ /pubmed/33568895 http://dx.doi.org/10.2147/OPTH.S296345 Text en © 2021 Ashkenazy et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ashkenazy, Noy
Goduni, Lediana
Smiddy, William E
Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
title Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
title_full Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
title_fullStr Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
title_full_unstemmed Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
title_short Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
title_sort short-term effects of covid-19-related deferral of intravitreal injection visits
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868644/
https://www.ncbi.nlm.nih.gov/pubmed/33568895
http://dx.doi.org/10.2147/OPTH.S296345
work_keys_str_mv AT ashkenazynoy shorttermeffectsofcovid19relateddeferralofintravitrealinjectionvisits
AT godunilediana shorttermeffectsofcovid19relateddeferralofintravitrealinjectionvisits
AT smiddywilliame shorttermeffectsofcovid19relateddeferralofintravitrealinjectionvisits